17 Feb
European Cancer Conference and American College of Gastroenterology: Prostate Cancer
Metastatic castrate-resistant prostate cancers (i.e., those that do not respond to androgen-deprivation therapy) typically overexpress receptors for vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), two of the key cell-surface targets for sunitinib (Sutent, Pfizer). Oral suni-tinib has emerged as a first-line therapy for renal cell carcinoma and as a treatment of gastrointestinal [...]